Multiple myeloma: Maintenance therapy after autologous hematopoietic stem cell transplantation, depending on minimal residual disease

Multiple myeloma: Maintenance therapy after autologous hematopoietic stem cell transplantation, depending on minimal residual disease

Aim. To determine the efficiency of maintenance therapy with bortezomib in patients with multiple myeloma (MM) who have achieved complete remission (CR) after autologous hematopoietic stem cell (auto-HSCT), depending on the presence of minimal residual disease (MRD). Subjects and methods. In January...

Full description

Bibliographic Details
Main Authors: M V Solovyev, L P Mendeleeva, O S Pokrovskaya, M V Nareyko, M V Firsova, I V Galtseva, Yu O Davydova, N M Kapranov, L A Kuzmina, E G Gemdzhian, V G Savchenko
Format: Article
Language:Russian
Published: "Consilium Medicum" Publishing house 2017-07-01
Series:Терапевтический архив
Subjects:
multiple myeloma
minimal residual disease
autologous hematopoietic stem cell transplantation
maintenance therapy
Online Access:https://ter-arkhiv.ru/0040-3660/article/viewFile/32258/pdf

Internet

https://ter-arkhiv.ru/0040-3660/article/viewFile/32258/pdf

Similar Items